Research
Hormonal
Breast cancer risk increased with duration of unopposed estrogen use.
Longer durations of unopposed estrogen therapy may necessitate closer monitoring for breast cancer risk.
GoodSupportsmedium confidence
Breast cancer risk increased with duration of unopposed estrogen use among longer-term users.
Why this rating
Based on a prospective cohort study design.
Source
Unopposed Estrogen Therapy and the Risk of Invasive Breast Cancer
Wendy Y. Chen et al. · Archives of Internal Medicine · 2006
DOI 10.1001/archinte.166.9.1027
cohort · n=28835Cited 249×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →